NCT00088166 2014-08-13
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Celtic Pharma Development Services
Phase 3 Completed
Clinical Trials
4 trialsNCT01369121 2013-07-30
Tolerability Study of Xerecept® in Pediatric Patients
Celtic Pharma Development Services
Phase 1/2 Terminated
NCT00226655 2012-08-31
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Celtic Pharma Development Services
Phase 3 Completed
NCT00226668 2008-01-03
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
Celtic Pharma Development Services
Phase 3 Withdrawn